Myra Kleinpeter, MD
Nephrology · New Orleans, LANPI 1184717498
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,594 of the $7,414 with a category attached, or 62.0%. 21 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 44.6% of the total. Reporting peaked in 2024 at $3,782 and has fallen 90.1% since, to $375 in 2025.
Across 65 payments — averaging $114.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$3K
- Mallinckrodt Hospital Products Inc.$624
- Gilead$515
- Mallinckrodt Enterprises LLC$301
- Sanofi$292
- Vifor Pharma, Inc.$287
- plus $2K from 15 others
Across 16 payments — averaging $76.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1K
What the payments were for
- Consulting fees$1,90026%
- Travel & lodging$76610%
- Food & beverage$4,59462%
- Education$1532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 6 | $3,308 |
| Mallinckrodt Hospital Products Inc. | 6 | $624 |
| Gilead | 7 | $515 |
| Mallinckrodt Enterprises LLC | 5 | $301 |
| Sanofi | 4 | $292 |
| Vifor Pharma, Inc. | 4 | $287 |
| Amgen | 3 | $267 |
| Vantive US Healthcare LLC | 2 | $222 |
| Fresenius USA Marketing, Inc. | 4 | $215 |
| Outset Medical Inc | 3 | $200 |
| Otsuka America Pharmaceutical, Inc. | 4 | $167 |
| Travere Therapeutics, Inc. | 2 | $156 |
| Aurinia Pharma U.S., Inc. | 2 | $146 |
| AstraZeneca | 3 | $145 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| OPKO Pharmaceuticals, LLC | 1 | $116 |
| Johnson & Johnson | 1 | $106 |
| Akebia Therapeutics Inc | 4 | $82 |
| Pfizer | 1 | $61 |
| Regeneron Healthcare Solutions, Inc. | 1 | $57 |
| Baxter Healthcare | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,414 in reported general payments places this provider in the 80th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 40 | $63,611 |
| Sevelamer Carbonate | 111 | $31,343 |
| JanuviaSitagliptin Phosphate | 16 | $18,986 |
| EntrestoSacubitril/Valsartan | 14 | $12,823 |
| ProsolParenteral Amino Acid 20% No.1 | 60 | $8,901 |
| Calcium Acetate | 24 | $1,708 |
| Labetalol Hcl | 18 | $714 |
| Famotidine | 31 | $535 |
| Midodrine Hcl | 13 | $444 |
| Atorvastatin Calcium | 38 | $398 |
| Metoprolol Succinate | 30 | $354 |
| Amlodipine Besylate | 75 | $338 |
| Hydralazine Hcl | 33 | $321 |
| Carvedilol | 40 | $284 |
| Dicyclomine Hcl | 13 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $215 | $63,61140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 206 nephrology providers in Louisiana.
Other nephrology in New Orleans
- Juan Carlos VelezNew Orleans$282K
- Michael TouchyNew Orleans$56K
- Juan MedauraNew Orleans$14K
- Farshid YazdiNew Orleans$14K
- Mihran NaljayanNew Orleans$10K
- Rhea BhargavaNew Orleans$9K
- April FoxNew Orleans$8K
- Joshua LowentrittNew Orleans$7K
- Angela ReginelliNew Orleans$6K
- Francisco CruzNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.